Women with HER2-positive early breast cancer achieved similar disease-free survival with 6 months of adjuvant trastuzumab compared with a 12-month duration, according to the phase III PERSEPHONE trial.
While HCT is an important benefit for FL patients, the optimal approach remains up for debate.
A retrospective study shows 30 patients need to be treated with adjuvant therapy to prevent 1 death at 3 years.
Researchers from MD Anderson say their study results "open the field of immunoprevention in LS to checkpoint inhibitors as an immune interception strategy."
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome.
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found.
The approval includes adults with R/R DLBCL after two or more lines of prior systemic therapy, high-grade B-cell lymphoma, and DLBCL arising from FL.
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy.
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk.
Achieving undetectable MRD after chemoimmunotherapy predicted longer progression-free and overall survival in CLL patients.